NVO News

Latest NVO News

• Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Arcus Biosciences (RCUS) and BioNTech SE (BNTX)
  TipRanks Newsroom · Oct 14, 2026
• Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme
  TipRanks Auto-Generated Newsdesk · Oct 13, 2026
• AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
  Ran Melamed · Oct 7, 2026
• Deutsche Bank Keeps Their Sell Rating on Novo Nordisk (0QIU)
  TipRanks Auto-Generated Intelligence Newsdesk · Oct 7, 2026
• Novo Nordisk Probes Patient Priorities in German Hemophilia A Study
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 6, 2026
• J.P. Morgan Sticks to Their Hold Rating for Novo Nordisk (0QIU)
  TipRanks Auto-Generated Intelligence Newsdesk · Oct 5, 2026
• Novo Nordisk Tests Zenagamtide Dosing to Sharpen Its Obesity Drug Pipeline
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 2, 2026
• Novo Nordisk Opens a New Front in Cardiometabolic Care With Early-Stage Anti-Inflammatory Study
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 30, 2026
• Novo Nordisk Tests Cagrisema Switch Strategy to Strengthen Its Diabetes Franchise
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 30, 2026
• Deutsche Bank Remains a Sell on Novo Nordisk (0QIU)
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 29, 2026
• Novo Nordisk (0QIU) Receives a Hold from Bank of America Securities
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 25, 2026
• Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Alcon (ALC)
  TipRanks Newsroom · Sep 23, 2026
• Novo Nordisk (NVO) Receives a Hold from Jefferies
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 22, 2026
• Roche Stock (RHHBY) Rises as New Obesity Drug Promises to Slash Weight By a Fifth
  David Craik · Sep 22, 2026
• Deutsche Bank Sticks to Its Sell Rating for Novo Nordisk (0QIU)
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 22, 2026
• Novo Stock (NVO): Deutsche Bank Keeps Sell Rating, Says Growth Strategy ‘Underwhelming on Multiple Fronts’
  Solomon Oladipupo · Sep 22, 2026
• UBS Sticks to Its Hold Rating for Novo Nordisk (0QIU)
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 22, 2026
• Novo Resources Updates Corporate Presentation to Highlight Growth Strategy
  TipRanks Canadian Auto-Generated Newsdesk · Sep 21, 2026
• Jefferies Remains a Hold on Novo Nordisk (0QIU)
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 21, 2026
• Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial
  Solomon Oladipupo · Sep 21, 2026